European Academy of Dermatology and Venereology

A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.

The investigational extended-release tablet maintained therapeutic plasma levels while avoiding peaks linked to cardiovascular risk.

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

Bambusa Therapeutics reveals promising phase I trial results for BBT001, targeting atopic dermatitis with dual-action bispecific antibodies.

TRIV-509 is a dual KLK5/7 inhibitor that aims to address barrier dysfunction, inflammation, and itch in moderate to severe AD.

Explore groundbreaking research and insights from the EADV Congress 2025, highlighting advancements in dermatology treatments and patient care.

Phase 1a results showing STAR-0310’s half-life of up to 68 days, durable cytokine inhibition, and a favorable safety profile will be presented in full at EADV 2025.

Evidence presented at EADV supports upadacitinib’s long-term use in atopic dermatitis and other inflammatory conditions.

Patients switched from placebo to remibrutinib at week 24 showed similar reductions in autoantibodies by week 52.

At week 16, up to 61% mean EASI reduction was observed in high-dose patients versus 31% in placebo.

Catch up on coverage from the third day of the European Academy of Dermatology and Venereology Congress 2025 held in Paris, France.

Treatment with APG777 led to a significant 71.0% reduction in EASI scores from baseline to week 16, compared to a 33.8% reduction with placebo, according to data presented at EADV 2025.

Galvokamig, a biologic targeting IL-13 and IL-17A/F, demonstrated significant benefits in moderate to severe atopic dermatitis.

Late-breaking EADV 2025 presentations highlighted positive efficacy outcomes in the adolescent population and pooled safety data across 5 phase 2b and phase 3 trials of delgocitinib cream.

Together with earlier trials presented at EADV, these findings support OX40 receptor inhibition as a promising therapeutic approach for AD.

The oral degrader produced biomarker reductions consistent with or superior to dupilumab, according to data presented at EADV 2025.

At EADV 2025, she showcased how OX40 and JAK inhibition offer complementary approaches to long-term disease control.

Catch up on coverage from the second day of the European Academy of Dermatology and Venereology Congress 2025 held in Paris, France.

Major unmet needs in pediatric AD include rapid itch relief, access, affordability, and better options for sensitive skin.

Findings from a large retrospective study presented at EADV 2025 suggest psoriasis significantly increases the risk of both wet and dry age-related macular degeneration.

LEO Pharma unveils promising phase 2b trial results for temtokibart, showcasing significant improvements in atopic dermatitis at EADV Congress 2025.

Presented at EADV Congress 2025, galvokimig showed promising early results in treating moderate to severe atopic dermatitis, targeting multiple inflammatory pathways for effective relief.

Data presented at EADV 2025 on the ROCKET-SHUTTLE trial demonstrate that rocatinlimab, a T-cell rebalancing therapy, significantly improves the signs and symptoms of moderate to severe AD in adults when used with topical therapies.

Balinatunfib was generally well tolerated, with common adverse events such as nausea and arthralgia also observed in placebo groups, according to data from EADV 2025.

Almirall's POSITIVE study, presented at EADV 2025, prioritizes patient well-being, showcasing the holistic impact of advanced treatments.

A meaningful difference in WI-NRS scores was observed as early as day 3 of treatment with ruxolitinib cream.

Catch up on coverage from the first day of the 2025 European Academy of Dermatology and Venereology Congress held in Paris, France.

At the 2025 EADV Congress in Paris, phase 3 ICONIC-ADVANCE data showed icotrokinra outperformed deucravacitinib in moderate to severe psoriasis.

A new study at EADV 2025 links atopic dermatitis to increased suicidal ideation, highlighting the condition's severe psychological impact.

The trial presented at EADV 2025 confirmed that icotrokinra’s efficacy is consistent with injectable IL-23 inhibitors while offering an oral option.